Pathogenesis of Graves Ophthalmopathy: Implications for Prediction, Prevention, and Treatment

American Journal of Ophthalmology

Volumn 142, Issue 1, 2006, Pages

  Garrity, James A ^a   Bahn, Rebecca S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; HYALURONIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; PREDNISONE; RADIOACTIVE IODINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SOMATOMEDIN C RECEPTOR; THIAMAZOLE; THYROTROPIN RECEPTOR;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; CELL DIFFERENTIATION; CONNECTIVE TISSUE; EDEMA; ENDOCRINE OPHTHALMOPATHY; FIBROBLAST; HUMAN; IMMUNOREGULATION; LYMPHOCYTIC INFILTRATION; MEDICAL INFORMATION; NONHUMAN; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 33745661418     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.02.047     Document Type: Article

References (35)

1. Bahn R.S., and Heufelder A.E. Pathogenesis of Graves ophthalmopathy. N Engl J Med 329 (1993) 1468-1475
2. Peyster R.G., Ginsberg F., Silber J.H., and Adler L.P. Exophthalmos caused by excessive fat. CT volumetric analysis and differential diagnosis. AJR Am J Roentgenol 146 (1986) 459-464
3. Bahn R.S. Clinical review 157: pathophysiology of Graves ophthalmopathy: The cycle of disease. J Clin Endocrinol Metab 88 (2003) 1939-1946
4. Smith T.J., Koumas L., Gagnon A., et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87 (2002) 385-392
5. Fatourechi V., Bartley G.B., Eghbali-Fatourechi G.Z., Powell C.C., Ahmed D.D., and Garrity J.A. Graves dermopathy and acropachy are markers of severe Graves ophthalmopathy. Thyroid 13 (2003) 1141-1144
6. Smith T.J., Wang H.S., and Evans C.H. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol 268 (1995) C382-C388
7. Sempowski G.D., Rozenblit J., Smith T.J., and Phipps R.P. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol 274 (1998) C707-C714
8. Adams M., Montague C.T., Prins J.B., et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100 (1997) 3149-3153
9. Rapoport B., Alsabeh R., Aftergood D., and McLachlan S.M. Elephantiasic pretibial myxedema. insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves disease. Thyroid 10 (2000) 685-692
10. Bartalena L., Marcocci C., Bogazzi F., et al. Relation between therapy for hyperthyroidism and the course of Graves ophthalmopathy. N Engl J Med 338 (1998) 73-78
11. Gerding M.N., van der Meer J.W., Broenink M., Bakker O., Wiersinga W.M., and Prummel M.F. Association of thyrotrophin receptor antibodies with the clinical features of Graves ophthalmopathy. Clin Endocrinol (Oxf) 52 (2000) 267-271
12. Marcus C., Ehren H., Bolme P., and Arner P. Regulation of lipolysis during the neonatal period. importance of thyrotropin. J Clin Invest 82 (1988) 1793-1797
13. Heufelder A.E., Dutton C.M., Sarkar G., Donovan K.A., and Bahn R.S. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves ophthalmopathy and pretibial dermopathy. Thyroid 3 (1993) 297-300
14. Feliciello A., Porcellini A., Ciullo I., et al. Expression of thyrotropin-receptor mRNA in healthy and Graves disease retro-orbital tissue. Lancet 342 (1993) 337-338
15. Starkey K.J., Janezic A., Jones G., et al. Adipose thyrotrophin receptor expression is elevated in Graves and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol 30 (2003) 369-380
16. Bahn R.S., Dutton C.M., Natt N., et al. Thyrotropin receptor expression in Graves orbital adipose/connective tissues. potential autoantigen in Graves ophthalmopathy. J Clin Endocrinol Metab 83 (1998) 998-1002
17. Wakelkamp I.M., Bakker O., Baldeschi L., Wiersinga W.M., and Prummel M.F. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves ophthalmopathy patients. Clin Endocrinol (Oxf) 58 (2003) 280-287
18. Valyasevi R.W., Erickson D.Z., Harteneck D.A., et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 84 (1999) 2557-2562
19. Valyasevi R.W., Harteneck D.A., Dutton C.M., and Bahn R.S. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ) and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 87 (2002) 2352-2358
20. Kumar S., Coenen M.J., Scherer P.E., and Bahn R.S. Evidence for enhanced adipogenesis in the orbits of patients with Graves ophthalmopathy. J Clin Endocrinol Metab 89 (2004) 930-935
21. Many M.-C., Costagliola S., Detrait M., Denef J.-F., Vassart G., and Ludgate M. Development of an animal model of autoimmune thyroid eye disease. J Immunol 162 (1999) 4966-4974
22. Baker G., Mazziotti G., von Ruhland C., and Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of Graves disease and ophthalmopathy. Endocrinology 146 (2005) 835-844
23. Pritchard J., Horst N., Cruikshank W., and Smith T.J. Igs from patients with Graves disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168 (2002) 942-950
24. Pritchard J., Han R., Horst N., Cruikshank W.W., and Smith T.J. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170 (2003) 6348-6354
25. Bartalena L., Martino E., Marcocci C., et al. More on smoking habits and Graves ophthalmopathy. J Endocrinol Invest 12 (1989) 733-737
26. Prummel M.F., and Wiersinga W.M. Smoking and risk of Graves disease. JAMA 269 (1993) 479-482
27. Eckstein A., Quadbeck B., Mueller G., et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87 (2003) 773-776
28. Burch H.B., Lahiri S., Bahn R.S., and Barnes S. Superoxide radical production stimuates retroocular fibroblast proliferation in Graves ophthalmopathy. Exp Eye Res 65 (1997) 311-316
29. Hofbauer L.C., Muhlberg T., Konig A., Heufelder G., Schworm H.D., and Heufelder A.E. Soluble interleukin-1 receptor agonist serum levels in smokers and nonsmokers with Graves ophthalmopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab 82 (1997) 2244-2247
30. Gamstedt A., Wadman B., and Karlsson A. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves disease. J Clin Endocrinol Metab 62 (1986) 773-777
31. Kumar S., and Bahn R.S. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves ophthalmopathy. J Clin Endocrinol Metab 88 (2003) 4246-4250
32. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 48 (2003) 3013-3022
33. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61 (2002) 883-888
34. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
35. Starkey K., Heufelder A., Baker G., et al. Peroxisome proliferator-activated receptor-γ in thyroid eye disease. contraindication for thiazolidinedione use?. J Clin Endocrinol Metab 88 (2003) 55-59